Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab.

Anastasilakis AD, Toulis KA, Polyzos SA, Anastasilakis CD, Makras P.

Ther Clin Risk Manag. 2012;8:295-306. doi: 10.2147/TCRM.S24239.

2.

Treatment of osteoporosis with denosumab.

Lewiecki EM.

Maturitas. 2010 Jun;66(2):182-6. doi: 10.1016/j.maturitas.2010.02.008. Review.

PMID:
20236778
3.

Denosumab in osteoporosis and oncology.

Burkiewicz JS, Scarpace SL, Bruce SP.

Ann Pharmacother. 2009 Sep;43(9):1445-55. doi: 10.1345/aph.1M102. Review.

PMID:
19622756
4.

The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.

Harris KB, Nealy KL, Jackson DJ, Thornton PL.

J Pharm Pract. 2012 Jun;25(3):310-8. doi: 10.1177/0897190012442061. Review.

PMID:
22550161
5.

[Updates of denosumab, anti-RANKL antibody for osteoporosis].

Tokuyama N, Tanaka S.

Clin Calcium. 2014 Jan;24(1):85-91. doi: CliCa14018591. Review. Japanese.

PMID:
24369284
6.

Update on denosumab treatment in postmenopausal women with osteoporosis.

Min YK.

Endocrinol Metab (Seoul). 2015 Mar 27;30(1):19-26. doi: 10.3803/EnM.2015.30.1.19. Review.

7.

Denosumab in postmenopausal osteoporosis: what the clinician needs to know.

Lewiecki EM.

Ther Adv Musculoskelet Dis. 2009 Feb;1(1):13-26. doi: 10.1177/1759720X09343221.

8.

Denosumab in osteoporosis.

Diab DL, Watts NB.

Expert Opin Drug Saf. 2014 Feb;13(2):247-53. doi: 10.1517/14740338.2014.860133. Review.

PMID:
24289327
9.

A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis.

Miller PD.

Ther Adv Musculoskelet Dis. 2011 Dec;3(6):271-82. doi: 10.1177/1759720X11424220.

10.

Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis.

Törring O.

Ther Adv Musculoskelet Dis. 2015 Jun;7(3):88-102. doi: 10.1177/1759720X15579189. Review.

11.

Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective.

Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, Reid IR, Vanderschueren D, Cosman F.

J Bone Miner Res. 2012 May;27(5):963-74. doi: 10.1002/jbmr.1570. Review. Erratum in: J Bone Miner Res. 2012 Nov;27(11):2414-5. J Bone Miner Res. 2012 Nov;27(11):2416.

12.

[Osteoporosis treatment by anti-RANKL antibody].

Sugimoto T.

Clin Calcium. 2011 Aug;21(8):1209-15. doi: CliCa110812091215. Review. Japanese.

PMID:
21814027
13.

Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis.

Miller PD.

Expert Opin Pharmacother. 2003 Dec;4(12):2253-8. Review.

PMID:
14640924
14.
15.

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.

Lewiecki EM.

Drug Healthc Patient Saf. 2011;3:79-91. doi: 10.2147/DHPS.S7727.

16.

Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis.

Yassin MA, Soliman AT, De Sanctis V, Abdelrahman MO, Aziz Bedair EM, AbdelGawad M.

Indian J Endocrinol Metab. 2014 Jul;18(4):546-51. doi: 10.4103/2230-8210.137516.

17.

Denosumab: a promising drug for the prevention and treatment of osteoporosis.

Lewiecki EM.

Womens Health (Lond). 2006 Jul;2(4):517-25. doi: 10.2217/17455057.2.4.517.

PMID:
19803959
18.

Safety Observations With Three Years of Denosumab Exposure: Comparison Between Subjects Who Received Denosumab During the Randomized FREEDOM Trial and Subjects Who Crossed Over to Denosumab During the FREEDOM Extension.

Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG.

J Bone Miner Res. 2017 Mar 9. doi: 10.1002/jbmr.3119. [Epub ahead of print]

PMID:
28277603
19.

Denosumab for the treatment of osteoporosis.

Zaheer S, LeBoff M, Lewiecki EM.

Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):461-70. doi: 10.1517/17425255.2015.1000860. Review.

20.

Osteoporosis: trials and tribulations.

Seeman E.

Am J Med. 1997 Aug 18;103(2A):74S-87S; discussion 87S-89S. Review.

PMID:
9302899

Supplemental Content

Support Center